vs
ICU MEDICAL INC（ICUI）与RENASANT CORP（RNST）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是RENASANT CORP的2.0倍（$540.7M vs $273.8M），RENASANT CORP净利率更高（32.2% vs -2.9%，领先35.1%），过去两年RENASANT CORP的营收复合增速更高（29.3% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
瑞耐桑特银行是美国密西西比州图珀洛的区域商业金融机构，母公司为瑞耐桑特公司，在阿拉巴马、佛罗里达、佐治亚、密西西比、路易斯安那、田纳西、北卡罗来纳、南卡罗来纳八州拥有280多家分支机构，旗下还运营内容平台“瑞耐桑特国度”，发布博客及节目内容。
ICUI vs RNST — 直观对比
营收规模更大
ICUI
是对方的2.0倍
$273.8M
净利率更高
RNST
高出35.1%
-2.9%
两年增速更快
RNST
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $273.8M |
| 净利润 | $-15.7M | $88.2M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | — |
| 净利率 | -2.9% | 32.2% |
| 营收同比 | -14.1% | — |
| 净利润同比 | 34.0% | 112.5% |
| 每股收益（稀释后） | $-0.63 | $0.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRNST
| Q1 26 | — | $273.8M | ||
| Q4 25 | $540.7M | $278.4M | ||
| Q3 25 | $537.0M | $269.5M | ||
| Q2 25 | $548.9M | $267.2M | ||
| Q1 25 | $604.7M | $170.7M | ||
| Q4 24 | $629.8M | $167.1M | ||
| Q3 24 | $589.1M | $220.3M | ||
| Q2 24 | $596.5M | $163.8M |
净利润ICUIRNST
| Q1 26 | — | $88.2M | ||
| Q4 25 | $-15.7M | $78.9M | ||
| Q3 25 | $-3.4M | $59.8M | ||
| Q2 25 | $35.3M | $1.0M | ||
| Q1 25 | $-15.5M | $41.5M | ||
| Q4 24 | $-23.8M | $44.7M | ||
| Q3 24 | $-33.0M | $72.5M | ||
| Q2 24 | $-21.4M | $38.8M |
毛利率ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — |
营业利润率ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | 1.0% | 34.8% | ||
| Q3 25 | 2.6% | 27.9% | ||
| Q2 25 | 1.9% | 1.0% | ||
| Q1 25 | 2.1% | 30.4% | ||
| Q4 24 | 6.0% | 29.8% | ||
| Q3 24 | 1.4% | 44.2% | ||
| Q2 24 | 1.3% | 29.6% |
净利率ICUIRNST
| Q1 26 | — | 32.2% | ||
| Q4 25 | -2.9% | 28.4% | ||
| Q3 25 | -0.6% | 22.2% | ||
| Q2 25 | 6.4% | 0.4% | ||
| Q1 25 | -2.6% | 24.3% | ||
| Q4 24 | -3.8% | 26.8% | ||
| Q3 24 | -5.6% | 32.9% | ||
| Q2 24 | -3.6% | 23.7% |
每股收益（稀释后）ICUIRNST
| Q1 26 | — | $0.94 | ||
| Q4 25 | $-0.63 | $0.78 | ||
| Q3 25 | $-0.14 | $0.63 | ||
| Q2 25 | $1.43 | $0.01 | ||
| Q1 25 | $-0.63 | $0.65 | ||
| Q4 24 | $-0.97 | $0.70 | ||
| Q3 24 | $-1.35 | $1.18 | ||
| Q2 24 | $-0.88 | $0.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.2B |
| 总债务越低越好 | — | $806.2M |
| 股东权益账面价值 | $2.1B | $3.9B |
| 总资产 | $4.1B | $27.1B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资ICUIRNST
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $308.6M | $1.1B | ||
| Q3 24 | $312.5M | $1.3B | ||
| Q2 24 | $302.6M | $851.9M |
总债务ICUIRNST
| Q1 26 | — | $806.2M | ||
| Q4 25 | — | $499.8M | ||
| Q3 25 | — | $558.9M | ||
| Q2 25 | — | $557.0M | ||
| Q1 25 | — | $433.3M | ||
| Q4 24 | — | $430.6M | ||
| Q3 24 | — | $433.2M | ||
| Q2 24 | — | $428.7M |
股东权益ICUIRNST
| Q1 26 | — | $3.9B | ||
| Q4 25 | $2.1B | $3.9B | ||
| Q3 25 | $2.1B | $3.8B | ||
| Q2 25 | $2.1B | $3.8B | ||
| Q1 25 | $2.0B | $2.7B | ||
| Q4 24 | $2.0B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $2.0B | $2.4B |
总资产ICUIRNST
| Q1 26 | — | $27.1B | ||
| Q4 25 | $4.1B | $26.8B | ||
| Q3 25 | $4.1B | $26.7B | ||
| Q2 25 | $4.1B | $26.6B | ||
| Q1 25 | $4.2B | $18.3B | ||
| Q4 24 | $4.2B | $18.0B | ||
| Q3 24 | $4.3B | $18.0B | ||
| Q2 24 | $4.3B | $17.5B |
负债/权益比ICUIRNST
| Q1 26 | — | 0.21× | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | $271.5M | ||
| Q3 25 | $56.7M | $135.5M | ||
| Q2 25 | $11.2M | $-77.3M | ||
| Q1 25 | $51.3M | $106.2M | ||
| Q4 24 | $40.2M | $106.4M | ||
| Q3 24 | $36.1M | $-1.7M | ||
| Q2 24 | $82.0M | $-49.1M |
自由现金流ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | $237.8M | ||
| Q3 25 | $27.6M | $120.1M | ||
| Q2 25 | $-8.5M | $-87.5M | ||
| Q1 25 | $36.7M | $101.3M | ||
| Q4 24 | $16.1M | $92.8M | ||
| Q3 24 | $16.2M | $-5.3M | ||
| Q2 24 | $62.5M | $-52.6M |
自由现金流率ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 85.4% | ||
| Q3 25 | 5.1% | 44.6% | ||
| Q2 25 | -1.5% | -32.7% | ||
| Q1 25 | 6.1% | 59.4% | ||
| Q4 24 | 2.6% | 55.5% | ||
| Q3 24 | 2.7% | -2.4% | ||
| Q2 24 | 10.5% | -32.1% |
资本支出强度ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 12.1% | ||
| Q3 25 | 5.4% | 5.7% | ||
| Q2 25 | 3.6% | 3.8% | ||
| Q1 25 | 2.4% | 2.8% | ||
| Q4 24 | 3.8% | 8.2% | ||
| Q3 24 | 3.4% | 1.6% | ||
| Q2 24 | 3.3% | 2.1% |
现金转化率ICUIRNST
| Q1 26 | — | — | ||
| Q4 25 | — | 3.44× | ||
| Q3 25 | — | 2.27× | ||
| Q2 25 | 0.32× | -75.92× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | -0.02× | ||
| Q2 24 | — | -1.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RNST
| Net Interest Income | $223.6M | 82% |
| Noninterest Income | $50.3M | 18% |
